trending Market Intelligence /marketintelligence/en/news-insights/trending/drhjngv8djuwtskmuf7ahw2 content esgSubNav
In This List

Matinas BioPharma appoints vice chairman

Blog

Insight Weekly: Bank boards lag on gender parity; future of office in doubt; US LNG exports leap

Blog

Insight Weekly: Job growth faces hurdles; shale firms sit on cash pile; Africa's lithium future

Blog

Insight Weekly: Loan growth picks up; US-China PE deals fall; France faces winter energy crunch

Blog

Perspectives from China: Chinese M&A in 2022


Matinas BioPharma appoints vice chairman

Matinas BioPharma Holdings Inc. appointed Patrick LePore as vice chairman of the board.

LePore served as the CEO, chairman and president of Par Pharmaceuticals Inc. from 2006 to 2012.

Matinas Biopharma said in a Sept. 6 news release that Lepore oversaw the sale of Par Pharmaceuticals to Texas Pacific Group for $2 billion in November 2012 and was appointed as the chairman. He oversaw the new company's $8 billion sale to Endo International PLC in 2015.

Matinas BioPharma is a clinical-stage biopharmaceutical company focused on developing innovative anti-infectives for orphan indications.